SWEEP
6.9.2022 09:54:37 CEST | Business Wire | Press release
Sweep, the leading carbon management and reduction platform, today announced it has expanded its leadership team with the recruitment of former French Minister of Agriculture and Food Julien Denormandie as Chief Impact Officer. He officially joined on September 5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005500/en/
Julien Denormandie (Photo: Cheick Saidou)
Julien Denormandie said: "I am thrilled to start this new chapter at Sweep. Recent years, and especially the last few months, have shown us that the fight against climate change is the challenge of the century. It also reminded us of the need to develop concrete, applicable solutions that generate results. Sweep perfectly aligns with this virtuous approach by helping companies to measure and reduce their carbon emissions. In my new role as Chief Impact Officer, I want to use my experience, coupled with the market-leading tools that Sweep has created, to support businesses in their climate journey and become agents of positive change in the low carbon economy.”
Julien Denormandie will work alongside Sweep’s four co-founders to pursue the efforts that have already established the French start-up as one of the fastest-growing climate tech firms and a trusted partner to organisations around the world.
The challenges of reducing carbon emissions are both related to the massive amount of data that needs to be collected and evaluated, and to network issues due to the vast number of stakeholders involved. Julien will be in charge of strengthening Sweep’s network approach to carbon management to help maximise the impact of their climate action. His remit will also include growing the business, both in France and internationally, and further establishing Sweep’s position as a leading partner to organisations committed to a low-carbon future.
Rachel Delacour, CEO and co-founder of Sweep said, "The challenge of reversing the spiral of climate change is massive. Our ambition is to help organisations transition to a model that will thrive in a low carbon economy. Julien Denormandie's arrival is at the heart of this ambition. He joins at a time when Sweep is entering a new stage of its growth and I am delighted that we will continue to develop our platform and offer together. He has a unique ability to solve complex, multidimensional problems, which is the very essence of the challenges facing organisations when reducing carbon emissions today. This is in Sweep's DNA and Julien's too!”
Minister of Agriculture and Food from July 2020 to May 2022 in Jean Castex's government, Julien Denormandie was previously Deputy to the Minister of Territorial Cohesion in the government of Edouard Philippe between June 2017 and October 2018 and then Minister in charge of Cities and Housing until July 2020. He was successively advisor to the Minister in charge of Foreign Trade, Nicole Bricq, to the Minister of Economy and Finance, Pierre Moscovici before becoming Deputy Chief of Staff of the Minister of Economy, under Emmanuel Macron between 2012 and 2016. Ingénieur des ponts, des eaux et des forêts, he began his career on secondment to the Department of External Relations of the Ministry of the Economy before holding various positions at the French Embassy in Cairo and at the Treasury Department.
About Sweep
Sweep helps businesses track and act on their carbon so they can become forever companies.
The data-driven platform makes it easy to understand, manage and reduce your carbon footprint. Powerful collaboration features and user-focused design empower your staff and your entire value chain to grow a cleaner business. The platform also has an integrated marketplace, letting you contribute to exciting carbon reduction and removal projects around the world. And with all your data in one place, its analytics offer deep insights into your progress and automatic reporting to your stakeholders.
Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition and The International Emissions Trading Association. Visit sweep.net to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
